Search results
Showing 556 to 570 of 1386 results for 0
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.
This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.
Intravenous fluid therapy in children and young people in hospital (QS131)
This quality standard covers managing intravenous (IV) fluids safely and effectively for babies, children and young people (from birth to 16) in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS131Show all sections
Sections for QS131
- Quality statements
- Quality statement 1: Measuring plasma electrolyte concentration and blood glucose
- Quality statement 2: Assessment of fluid balance
- Quality statement 3: Fluid type for intravenous (IV) fluid resuscitation
- Quality statement 4: Fluid type for routine maintenance
- Quality statement 5: Intravenous (IV) fluids lead
- About this quality standard
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)
Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making